Press Releases


Press Releases

Date Title and Summary
Toggle Summary Finacea(R) (azelaic acid) Foam 15%, Approved by U.S. FDA for Topical Treatment of the Inflammatory Papules and Pustules of Mild to Moderate Rosacea
REHOVOT, Israel and RALEIGH, N.C. , July 31, 2015 (GLOBE NEWSWIRE) -- As announced today by Bayer HealthCare , the U.S. Food & Drug Administration ( FDA ) has approved Finacea® (azelaic acid) Foam, 15% for topical treatment of the inflammatory papules and pustules of mild to moderate rosacea.
Toggle Summary Foamix -- with Late-Stage Candidates in Acne and Rosacea -- to Participate at American Academy of Dermatology Annual Meeting
REHOVOT, Israel and BRIDGEWATER, N.J. , Feb. 26, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) (“Foamix” or the “Company”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in
Toggle Summary Foamix Announces $16 Million Investment by OrbiMed
REHOVOT, Israel and BRIDGEWATER, N.J. , April 16, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today
Toggle Summary Foamix Announces $64 Million Capital Financing Investment by Perceptive Advisors and OrbiMed
Foamix secures up to $50 million in non-dilutive funding Company secures $14 million via a registered direct offering of equity REHOVOT, Israel and BRIDGEWATER, N.J. , July 30, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix”), a clinical stage specialty pharmaceutical
Toggle Summary Foamix Announces Additional Positive Topline Results from Third Phase 3 Trial (Study FX2017-22) Evaluating FMX101 Topical Minocycline Foam for Moderate-to-Severe Acne
Statistically significant improvement demonstrated in reduction of non-inflammatory lesions Dermal tolerability scores consistent with previous Phase 3 studies Re-analysis including patients from discontinued investigator site consistent with primary ITT analysis for both co-primary endpoints,
Toggle Summary Foamix Announces Appointment of Anthony Bruno to Board of Directors
REHOVOT, Israel and BRIDGEWATER, N.J. , Nov. 19, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today announced the
Toggle Summary Foamix Announces Appointment of Dr. Aaron Schwartz to Board of Directors
REHOVOT, Israel , and BRIDGEWATER, N.J. , May 7, 2015 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq:FOMX) ("Foamix"), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today
Toggle Summary Foamix Announces Appointment of Matt Wiley as Chief Commercial Officer
REHOVOT, Israel , and BRIDGEWATER, N.J. , Nov. 27, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today announced the
Toggle Summary Foamix Announces Appointment of Sharon Barbari to Board of Directors
REHOVOT, Israel , and BRIDGEWATER, N.J. , Jan. 23, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today announced the
Toggle Summary Foamix Announces Closing of its Follow-on Offering of Ordinary Shares and Full Exercise of its Option by the Underwriters
REHOVOT, Israel , and BRIDGEWATER, N.J. , Sept. 18, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (“Foamix”) (Nasdaq: FOMX), a clinical-stage specialty pharmaceutical company focused on developing and commercializing proprietary, topical therapies to address unmet needs in dermatology, today